San Diego, February 26

Welcome to hubXchange’s San Diego Antibody Therapeutics Xchange 2024, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing antibody therapeutics, through a series of roundtable discussions.
Discussion topics will cover Target Selection, Lead Identification & Optimization, Formats & Scaffolds, Bi/Multi-Specifics and Emerging Technologies.
Take advantage of this unique highly interactive meeting format designed for maximum engagement and collaboration with your peers.

Please note this is an In-Person meeting.

Handlery Hotel San Diego,
950 Hotel Circle North,
San Diego CA 92108


  • Computational approach for target selection
  • How to ensure target specificity to avoid unintended interactions with other proteins and molecule
  • Challenging membrane antibody targets: Brainstorming in-parallel in vivo and in vitro methodologies to identify rare and precious functional Ab candidates
  • One size doesn’t fit all: Key considerations for successful therapeutic antibody discovery for various modalities and indications
  • Fc engineering for improved antibody druggability
  • Considerations for CAR-T/ CAR-NK cell binder format designs during screening and selections
  • Developing bispecifics targeting novel targets
  • Immuno-oncology tumour-specific approach through multispecific therapeutics
  • Novel delivery modes for biologics – beyond parenteral administration and beyond classical protein administration
  • Using AI, AlphaFold and ML methods for therapeutics discovery and optimization

Full Xchange Agenda

Click on each track for detailed agenda

Target Selection

Titles and Bullets
8:00 – 8:30
8:30 – 9:00

Opening Address & Keynote Presentation

9:05 – 10:05
Different criteria for target selection depending on the type of biologic modality

Key issues in target selection:

  • therapeutic index,
  • resistance mechanisms,
  • OMICs platforms for target selection
Milutinovic has 20 years of experience in diverse oncology research areas and has been involved in driving several biologic and small molecule therapeutics into FIH studies. Deep understanding and experience in evaluating different target classes and resistance mechanisms has enabled her to identify strongly synergistic drug combinations and influence clinical strategies for patients with unmet needs.
Snezana Milutinovic
10:10 – 10:40
1-2-1 Meetings/Networking Break
10:40 – 11:10
1-2-1 Meetings/Networking Break
11:10 – 11:20
Morning refreshments
11:20 – 12:20
Sponsor-led Roundtable
12:20 – 13:20
Networking Lunch
13:20 – 13:50

Spotlight Presentation

13:50– 14:20
1-2-1 Meetings/Networking Break
14:20 – 14:50
1-2-1 Meetings/Networking Break
14:50 – 15:20
Poster Presentation
15:30 – 16:00
1-2-1 Meetings/Networking Break
16:05 – 17:05
Computational approach for target selection (Topic TBC)
17:05– 18:05
Drinks-Canape Reception


Antibody Therapeutics Xchange | San Diego 2024